US-based based generic pharmaceutical company Ingenus Pharmaceuticals announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for its Conjugated Estrogens Tablets, USP, the first FDA-approved generic equivalent to Premarin Tablets, and is launching the product commercially.
Conjugated Estrogens Tablets, USP are offered in all FDA-approved strengths: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg.
Indicated in the treatment of moderate to severe vasomotor symptoms due to menopause and the prevention of postmenopausal osteoporosis, the product is available to customers nationwide immediately.
Paul Dutra, Ingenus Pharmaceuticals executive vice president, said: "The availability of the first generic version of Premarin Tablets represents a significant step forward in expanding access to this important therapy."
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix
Avingtrans subsidiary Adaptix secures FDA clearance for 3D orthopaedic imaging system
Innate Pharma cleared by FDA to launch TELLOMAK 3 Phase 3 trial of lacutamab in CTCL
Exact Sciences secures US exclusive license to Freenome's blood-based colorectal cancer tests
MavriX Bio reports first patient dosed in Phase 1/2 trial of MVX-220 for AS
Johnson & Johnson's DARZALEX FASPRO receives US FDA approval
Calico Life Sciences' ABBV-CLS-628S granted US FDA Orphan Drug Designation
Galderma secures US FDA approval for Restylane Lyft to enhance chin profile
Spinogenix reveals positive SPG302 topline results from Phase 2a study for treatment of ALS
iLeukon reports FDA clearance of IND application for phase II study of ILKN421H in advanced NSCLC
AVEO Oncology signs development and option agreement with HiberCell